Onconetix (ONCO) Stock News, May 2025-Mar 2026

Realbotix (ONCO) agreed on February 11, 2026 to sell 100% of its subsidiary Realbotix, LLC to NASDAQ-listed Onconetix (NASDAQ: ONCO) in an all-stock deal.

Realbotix will receive a variable 75%–90% stake of ONCO post-close, retain control of Abyss Creations, and can appoint four of five ONCO directors. Closing is expected before end of Q3 2026.

Onconetix (Nasdaq: ONCO) will acquire Realbotix LLC in an all-stock share exchange that transfers 100% of Realbotix equity to Onconetix. The combined company expects to trade on Nasdaq and the deal is targeted to close in the second half of 2026.

Following closing, Realbotix Parent is expected to own between 75% and 90% of fully diluted common shares; Andrew Kiguel will become CEO of the combined company. Closing remains subject to shareholder and regulatory approvals in the US and Canada.

Onconetix (NASDAQ:ONCO), a biotechnology company focused on men's health and oncology, has announced multiple significant financial transactions. The company has secured a $12.9 million private placement through Series D Preferred Stock and Warrants, with $9.3 million paid in cash and the remainder offsetting existing debts.

The financing includes warrants to purchase up to 4,362,827 shares of common stock at an initial exercise price of $3.6896 per share. Additionally, Onconetix has settled its $8.8 million debt with Veru, Inc. through a combination of $6.3 million cash payment and conversion of $2.5 million into Series D Preferred Stock and warrants. The company has also terminated its previously planned merger with Ocuvex, Inc.

Onconetix (NASDAQ:ONCO) and Ocuvex Therapeutics have mutually agreed to terminate their merger agreement originally announced on July 16, 2025. The decision comes after both companies determined that pursuing independent paths would better serve their respective stakeholders.

Despite the merger termination, Ocuvex announced positive developments, including obtaining its New Jersey state pharmaceutical license and the upcoming commercial launch of Omlonti in the coming weeks. Both companies' leadership expressed confidence in their independent growth trajectories and maintained a collaborative spirit throughout the process.

Onconetix (NASDAQ:ONCO) announced that its subsidiary Proteomedix has entered into a licensing agreement with Immunovia AB for the manufacturing of key reagents used in their pancreatic cancer test PancreaSure. Under the agreement, Proteomedix will provide master cells for antibody production and intellectual property licenses for three of the five biomarkers in PancreaSure.

The deal includes payments totaling $700,000 to Proteomedix in 2025-2026, plus a 3% royalty on net sales of PancreaSure and related products from 2026 to 2032. The agreement enables Immunovia to purchase reagents directly from Proteomedix's supplier while maintaining their focus on Proclarix, their early prostate cancer detection test.

Onconetix (NASDAQ:ONCO) and privately-held Ocuvex Therapeutics have signed a definitive merger agreement in a significant stock-based transaction. Under the terms, Ocuvex shareholders will receive 90% ownership of the combined company, while Onconetix shareholders will retain 10% of the equity interests.

The merger will combine Ocuvex's pipeline of commercial and late clinical stage ophthalmic assets with Onconetix's public market presence. The combined company's board will consist of seven directors, with Ocuvex designating five and Onconetix appointing two. The transaction is expected to close in Q4 2025, subject to regulatory and stockholder approvals.

Onconetix (NASDAQ: ONCO) has received a favorable decision from the Nasdaq Hearings Panel regarding its continued listing status. The company must meet two key requirements: compliance with the Periodic Filing Listing Rule by June 13, 2025, and the Bid Price Listing Rule by June 30, 2025. Following a hearing on May 27, 2025, Onconetix has already achieved compliance with the Periodic Filing requirement by submitting its Form 10-Q for Q1 2025 on June 12. To address the bid price requirement, the company executed a 1-for-85 reverse stock split on June 13, 2025, and anticipates meeting the minimum bid price requirement by June 27, 2025.

Onconetix (NASDAQ: ONCO) announced a 1-for-85 reverse stock split following stockholder approval at a Special Meeting held on May 30, 2025. The split will be effective June 13, 2025, with the stock continuing to trade under symbol ONCO. This strategic move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse split will reduce outstanding shares from 44.4 million to approximately 521,863. Stockholders approved both the reverse split proposal (allowing a ratio between 1:10 to 1:150) and the adjournment proposal. The split will maintain the same ownership percentage for stockholders, except for fractional shares which will be compensated in cash based on the closing price on June 12, 2025. The action will also affect equity awards, convertible preferred stock, and warrants.

Onconetix (NASDAQ: ONCO) has received multiple delisting notices from Nasdaq due to several compliance issues. The company faces delisting threats due to: (1) failure to file its Q1 2025 10-Q report, (2) failure to file its 2024 annual 10-K report, and (3) non-compliance with the minimum bid price requirement of $1.00, with shares trading below $0.10 for ten consecutive days.

The company has requested a hearing before the Nasdaq Hearings Panel scheduled for May 27, 2025, which has temporarily stayed the trading suspension. Onconetix has also submitted a stay request on May 1, 2025. The company intends to file both missing reports to regain compliance, though there's no assurance the Panel will grant extensions.